A look at financing, M&A and alliance activity April–June 2017
• By Amanda Micklus and Maureen Riordan
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
Continuing the downward trend in financing over the past several quarters, the device industry collected $1.2 billion in Q2 funding, a 48% decrease from Q1's $2.3 billion total. It is worth noting, however, that Q1 did include a single outlier transaction worth $800 million (by Verily Life Sciences LLC[See Deal]), significantly boosting that quarter's value.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
